Ken Horisaki
11PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (11)
Sort by Publication Date:
|Feb 13, 2026
Clinical Outcomes of Dacarbazine After Failure of Immune Checkpoint Inhibitors: A Case Study of 15 Japanese Patients With Malignant Melanoma.Ken Horisaki, Shusuke Yoshikawa, Wataru Omata
|Jan 07, 2026
Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Stage IV Melanoma Receiving Immune Checkpoint Inhibitors: A Single-Center Retrospective Study.Ken Horisaki, Shusuke Yoshikawa, Wataru Omata
|Oct 07, 2025
C-Reactive Protein Kinetics as Prognostic Biomarkers in Stage IV-Melanoma Treated With Immune Checkpoint Inhibitors in the Japanese Population: A Single-Center, Retrospective Cohort Study.Ken Horisaki, Shusuke Yoshikawa, Wataru Omata
|Sep 06, 2025
Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First-Line Programmed Cell Death Protein 1 Monotherapy.Ken Horisaki, Shusuke Yoshikawa, Wataru Omata
|Jul 29, 2025
The Real-World Efficacy and Side Effects of Different Nivolumab Regimens in Japanese Patients with Advanced Melanoma: A Single-Center Retrospective Study.Ken Horisaki, Shusuke Yoshikawa, Wataru Omata
Pageof 2
